Accueil Recherche NouveautésEmail webmaster Tous les textes - FMCSommaire généralPage précédente
Prévention du cancer du sein par les AINS ?
BMC Cancer. 2003 Oct 31;3(1):28.

Les auteurs étudient l'influence de la prise régulière d'AINS, anti-inflammatoires non stéroïdiens, sur le risque de cancer du sein dans les des données du Women Health Initiative qui a porté sur 80 741 femmes ménopausées, âgées de 50 à 79 ans.

Les résultats ont montré que la prise régulière d'AINS, au moins 2 comprimés par semaine, pendant plusieurs années, réduisait l'incidence du cancer du sein de 20 à peut-être 50%.
L'estimation de la diminution du risque pour une utilisation prolongée de l'ibuprofène est supérieure a celle obtenue avec l'aspirine à dose anti-inflammatoire.
Le paracétamol et l'aspirine à faible dose, moins de 100 mg par jour, étaient sans effet protecteur.

Breast cancer and nonsteroidal anti-inflammatory drugs
prospective results from the Women's Health Initiative.

Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A; Women's Health Initiative.
The Ohio State University College of Medicine and Public Health, Columbus, Ohio 43210-1240, USA. harris.44@osu.edu

We analyzed data from the prospective Women's Health Initiative (WHI) Observational Study to examine the effects of regular use of aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) on breast cancer risk.
We studied a population of 80,741 postmenopausal women between 50 and 79 years of age who reported no history of breast cancer or other cancers (excluding nonmelanoma skin cancer), and we completed a personal baseline interview that elicited comprehensive health information including data on breast cancer risk factors and NSAID use.
All of the cases were adjudicated by WHI physicians using pathology reports. Our analysis was based on 1392 confirmed cases of breast cancer. Relative risks (RRs) with 95% confidence intervals (CIs) were estimated with adjustment for age and other breast cancer risk factors.

Regular NSAID use (two or more tablets/week) for 5-9 years produced a 21% reduction in the incidence of breast cancer (RR, 0.79; 95% CI, 0.60-1.04); regular NSAID use for 10 or more years produced a 28% reduction (RR, 0.72; CI, 0.56-0.91), and there was a statistically significant inverse linear trend of breast cancer incidence with the duration of NSAID use (P < 0.01).

The estimated risk reduction for long-term use of ibuprofen (RR, 0.51; CI, 0.28-0.96) was greater than for aspirin (RR, 0.79; CI, 0.60-1.03).

Subgroup analysis by breast cancer risk factors did not result in effect modification. Regular use of acetaminophen (an analgesic agent with little or no anti-inflammatory activity) or low-dose aspirin (<100 mg) was unrelated to the incidence of breast cancer.

Our results indicate that the regular use of aspirin, ibuprofen, or other NSAIDs may have a significant chemopreventive effect against the development of breast cancer and underscore the need for clinical trials to confirm this effect.
Accueil NouveautésEmail webmaster Sommaire FMC Sommaire généralPage précédente